Mednet Logo

How late after surgery would you consider prescribing osimertinib as adjuvant therapy in patients with resected EGFRm NSCLC?

Community PollStarted

How late after surgery would you consider prescribing osimertinib as adjuvant therapy in patients with resected EGFR+ NSCLC?

65 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Indiana University School of Medicine
Answered on

Most patients will received adjuvant chemotherapy for 3-4 cycles. Adjuvant chemo typically begins 4-12 weeks after surgery. Therefore, the initiation of adjuvant sequential Osimertinib would typically occur 3 weeks after the last cycle of chemotherapy.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of California Los Angeles
Answered on

This is also a tough question, particularly if a patient comes for a new consultation with you outside of the window that was allowed for the trial. On the trial, if a patient did not get adjuvant chemotherapy, he or she had to be randomized by 10 weeks after surgery, and if the patient did get adju...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Yale Cancer Center At Smilow Cancer Hospital
Answered on

While the trial allowed 12 weeks if no adjuvant therapy and up to 24 weeks for patients who received adjuvant therapy, I would stick with that.

Join for free or sign in to see the full answer